Phase II Trial Of PS-341 (Bortezomib) In Patients With Previously Treated Advanced Urothelial Tract Transitional Cell Carcinoma
PHASE2CompletedINTERVENTIONAL
Enrollment
40
Participants
Timeline
Start Date
October 31, 2003
Primary Completion Date
March 31, 2006
Conditions
Metastatic Transitional Cell Cancer of the Renal Pelvis and UreterRecurrent Bladder CancerRecurrent Transitional Cell Cancer of the Renal Pelvis and UreterRecurrent Urethral CancerStage III Bladder CancerStage III Urethral CancerStage IV Bladder CancerStage IV Urethral CancerTransitional Cell Carcinoma of the BladderUreter Cancer
Interventions
DRUG
bortezomib
Given IV
Trial Locations (1)
94115
UCSF-Mount Zion, San Francisco
All Listed Sponsors
lead
National Cancer Institute (NCI)
NIH
NCT00072150 - Phase II Trial Of PS-341 (Bortezomib) In Patients With Previously Treated Advanced Urothelial Tract Transitional Cell Carcinoma | Biotech Hunter | Biotech Hunter